Specifically, GPSM3 has emerged as a promising target for immunotherapy in GBM patients, due to its strong correlation with immune checkpoints and tumor microenvironment (TME) immunosuppressors in GBM [38]. The gene discussed is GPSM3; the disease is glioblastoma.